GH1 and myalgic encephalomeyelitis/chronic fatigue syndrome: The interactions between endocrine axes—such as the inhibitory effect of glucocorticoid on GH release (101)—described in ME/CFS and related studies also contribute to the rationale for peripheral hormone combination therapies (170–173).